Long-term investments in biosimilars delivering expected results: Biocon
Robust performance by the Biologics and Small Molecules business segments has fuelled a 25% growth in Q1FY20 revenues at Biocon Ltd., to Rs. 1,490-crore.
Revenue from Biologics grew by 96% to Rs. 490-crore, confirming the validity of the company’s long-term investment strategy of expansion of geographical footprint and increased penetration of products in key developed and emerging markets. Revenue from Small Molecules at Rs. 480-crore was driven by steady API sales and a multi-fold growth in Generic Formulations.
The consolidated EBITDA for Q1FY20 stood at Rs. 462-crore, up by 51%, and Net Profit (excluding exceptional item) at Rs. 223-crore, up by 86%.
Commenting on the results, Chairperson & Managing Director, Dr. Kiran Mazumdar-Shaw stated: “We remain committed to develop high quality bio-therapeutics and enable affordable access to patients across world markets.”
During the quarter the company initiated a greenfield project for a fermentation-based manufacturing facility at Visakhapatnam, Andhra Pradesh to cater to the anticipated strong volume growth in the Small Molecule APIs and Generic Formulations business.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Sinopec's New Environmental Protection Epichlorohydrin Process Initiated
Huntsman sells chemical intermediates and surfactants for nearly $2.1 billion
A series of detailed measures for stabilizing foreign trade have been introduced
Advantages and disadvantages of waterborne epoxy coatings and their applications
Coke's second round of raising pressure
Walgreens, the makeup chain, will close 200 American stores